公开(公告)号：WO2005092896A1

公开(公告)日：2005-10-06

申请号：PCT/KR2005/000019

申请日：2005-01-05

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  JEIL PHARMACEUTICAL CO., LTD. ,  YANG, Beom-Seok ,  YANG, Kyung-Mi ,  KIM, Hae-Jong ,  PARK, In-Sung ,  PARK, Sung-Dae ,  LEE, Jang-Hyuk ,  KWON, Hyuk-Man ,  WOO, Byoung-Young

Inventor： YANG, Beom-Seok ,  YANG, Kyung-Mi ,  KIM, Hae-Jong ,  PARK, In-Sung ,  PARK, Sung-Dae ,  LEE, Jang-Hyuk ,  KWON, Hyuk-Man ,  WOO, Byoung-Young

IPC: C07D491/048

CPC classification number: C07D491/04

Abstract: A new furopyrimidine compound, their pharmaceutically acceptable salt, and a tyrosine kinase activity inhibitor. The furopyrimidine compound is a compound defined by chemical formula 1, 2, 3 or 4, on their precursor, and can exist as a form of free base or in an acid-addition salt. Since the furopyrimidine compound has an effect of inhibiting activity of DDR2 tyrosine kinase, it can be used in treating illnesses caused by the DDR2 tyrosine kinase activity such as hepatocirrhosis, rheumatoid arthritis or cancer.

Abstract translation: 新的呋喃嘧啶化合物，其药学上可接受的盐和酪氨酸激酶活性抑制剂。 呋喃嘧啶化合物是化学式1,2,3或4所定义的化合物，它们的前体可以作为游离碱形式或在酸加成盐中存在。 由于呋喃嘧啶化合物具有抑制DDR2酪氨酸激酶活性的作用，因此可用于治疗由DDR2酪氨酸激酶活性引起的疾病，如肝硬化，类风湿性关节炎或癌症。

公开(公告)号：WO2005050721A1

公开(公告)日：2005-06-02

申请号：PCT/KR2003/002891

申请日：2003-12-30

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  JOO, Oh Shim ,  JUNG, Kwang-Deog ,  LOKHANDE, C., D. ,  PARK, Bong-Ok

Inventor： JOO, Oh Shim ,  JUNG, Kwang-Deog ,  LOKHANDE, C., D. ,  PARK, Bong-Ok

IPC: H01L21/20

CPC classification number: H01L28/65 ,  C25D3/52 ,  H01L21/2885

Abstract: A ruthenium oxide-thin film having a high specific capacitance can be prepared by a method which comprises the steps of immersing a working electrode-plate and a counter electrode in an electrodeposition bath containing a ruthenium salt, and applying a current between two electrodes, without further heat-treatment step at a low cost.

Abstract translation: 具有高比电容的氧化钌薄膜可以通过以下步骤制备：将工作电极板和对电极浸入含有钌盐的电沉积浴中并在两个电极之间施加电流的步骤，没有 进一步的热处理步骤以低成本。

公开(公告)号：WO2005026093A1

公开(公告)日：2005-03-24

申请号：PCT/KR2004/000156

申请日：2004-01-29

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  JUNG, Kwang-Deog ,  JOO, Oh-Shim ,  OH, Jun-Woo

Inventor： JUNG, Kwang-Deog ,  JOO, Oh-Shim ,  OH, Jun-Woo

IPC: C07C43/04

CPC classification number: B01J23/002 ,  B01J23/06 ,  B01J23/34 ,  B01J23/755 ,  B01J23/80 ,  B01J37/03 ,  B01J2523/00 ,  C07C41/01 ,  Y02P20/146 ,  B01J2523/27 ,  B01J2523/31 ,  B01J2523/72 ,  B01J2523/847 ,  C07C43/043

Abstract: The present invention is directed to a method for producing DME, which comprises separating a CO 2 rich stream from a crude product stream containing DME and CO 2 obtained by a DME synthesis from a feed syn gas; introducing the CO 2 rich stream to a reverse water gas shift (RWGS) reactor wherein it is reacted with hydrogen in the presence of a catalyst to provide a CO rich stream, and recycling the CO rich stream to the step of the methanol synthesis step. In accordance with the present invention, a large amount of carbon dioxide gas generated during the preparing process of DME is effectively re-used, thus increasing the yield of DME and lowering the amount of carbon dioxide discharged.

Abstract translation: 本发明涉及一种生产DME的方法，其包括从含有DME和通过DME合成得到的含有DME和CO 2的粗产物流从进料合成气中分离富CO2流; 将二氧化碳浓缩物流引入反向水煤气变换（RWGS）反应器中，其中在催化剂存在下与氢气反应以提供富CO流，并将富CO流再循环到甲醇合成步骤的步骤。 根据本发明，在DME的制备过程中产生的大量二氧化碳气体被有效地再利用，从而提高了DME的产率并降低了排出的二氧化碳的量。

公开(公告)号：WO2004088565A1

公开(公告)日：2004-10-14

申请号：PCT/KR2003/001630

申请日：2003-08-13

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  YOON, Chang-No ,  CHI, Myung-Whan

Inventor： YOON, Chang-No ,  CHI, Myung-Whan

IPC: G06F19/00

CPC classification number: G06F3/011

Abstract: The present invention relates to a method of designing peripheral equipment for molecular modeling system on a computer. In more detail, it relates to a method of designing peripheral equipment that provides intuitive input/output devices to a molecular modeling system so that a user can display a molecule on a computer and comprehend various characteristics of the molecule at once. By separating the screens corresponding to left/right eyes respectively, the present invention makes it possible to output a stereo-view of a molecule. In addition, for assisting a user to easily handle two or more molecules on a computer, the present invention provides gloves, a spatial location tracking instrument, and a force feedback joystick, which transfers the interaction force between two molecules to the user, as input devices in addition to the conventional computer input devices, a keyboard and a mouse.

Abstract translation: 本发明涉及一种在计算机上设计用于分子建模系统的外围设备的方法。 更详细地，涉及一种设计外围设备的方法，其向分子建模系统提供直观的输入/输出设备，使得用户可以在计算机上显示分子并一次性地了解分子的各种特征。 通过分开与左眼/右眼对应的画面，本发明使得可以输出分子的立体视图。 此外，为了帮助用户容易地处理计算机上的两个或更多个分子，本发明提供手套，空间位置跟踪装置和力反馈操纵杆，其将两个分子之间的相互作用力传递给用户作为输入 设备以及传统的计算机输入设备，键盘和鼠标。

公开(公告)号：WO2004009076A1

公开(公告)日：2004-01-29

申请号：PCT/KR2003/001442

申请日：2003-07-21

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun ,  KIM, Se-Woong ,  LEE, Seung-Ju

Inventor： CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun ,  KIM, Se-Woong ,  LEE, Seung-Ju

IPC: A61K31/337

CPC classification number: A61K47/06 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/337 ,  A61K47/14 ,  A61K47/44

Abstract: The present invention relates to a paclitaxel composition and the preparation methods thereof for the treatment of bladder cancer wherein said paclitaxel composition comprises 4~90% by weight of at least one selected from the monoglycerides, 0.01~90% by weight of at least one oil, 0.01~90% by weight of at least one emulsifier and 0.01~20% by weight of paclitaxel. The composition of the present invention can treat bladder cancer effectively since the composition solubilizes paclitaxel, does not form aggregates, adsorbs well on the bladder wall and penetrates into the muscle layer of the bladder.

Abstract translation: 本发明涉及紫杉醇组合物及其治疗膀胱癌的制备方法，其中所述紫杉醇组合物包含4〜90重量％的选自单酸甘油酯，0.01〜90重量％的至少一种油 ，0.01〜90重量％的至少一种乳化剂和0.01〜20重量％的紫杉醇。 本发明的组合物可以有效治疗膀胱癌，因为组合物溶解紫杉醇，不形成聚集体，在膀胱壁上很好地吸附并渗入膀胱的肌肉层。

公开(公告)号：WO2004009073A1

公开(公告)日：2004-01-29

申请号：PCT/KR2003/001441

申请日：2003-07-21

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun ,  YUK, Soon-Hong

Inventor： CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun ,  YUK, Soon-Hong

IPC: A61K31/245

CPC classification number: A61K9/5078 ,  A61K9/0095 ,  A61K9/5026 ,  A61K9/5031 ,  A61K31/14 ,  A61K31/245 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a new use of octylonium bromide as p-glycoprotein inhibitor to increase cellular uptake of drugs. More particularly, the present invention provides octylonium bromide as a p-glycoprotein inhibitor to increase cellular uptake of drugs such as anticancer drugs by taking octylonium bromide simultaneously with or proceding drug administration.

Abstract translation: 本发明涉及辛基溴化物作为P-糖蛋白抑制剂的新用途，以增加药物的细胞吸收。 更具体地，本发明提供了作为P-糖蛋白抑制剂的辛基溴化铵，以通过同时服用辛基溴或同时给予药物来增加药物如抗癌药物的细胞摄取。

公开(公告)号：WO2003037324A1

公开(公告)日：2003-05-08

申请号：PCT/KR2002/002010

申请日：2002-10-29

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  LEE, Yong Sup ,  PARK, Hokoon ,  JIN, Changbae ,  KIM, Hyoung Ja ,  CHO, Jungsook ,  PARK, Mijeong ,  SONG, Yunseon

Inventor： LEE, Yong Sup ,  PARK, Hokoon ,  JIN, Changbae ,  KIM, Hyoung Ja ,  CHO, Jungsook ,  PARK, Mijeong ,  SONG, Yunseon

IPC: A61K31/352

CPC classification number: A61K31/352 ,  A61K36/33

Abstract: The present invention relates to a use of an ethyl acetate extract of Opuntia ficus-indica and compounds isolated therefrom for preventing and treating brain diseases such as Alzheimer's disease stroke and Parkinson's disease, cell and tissue damage caused by ischemia, or cardiovascular system disease such as myocardial infarction.

Abstract translation: 本发明涉及猕猴桃的乙酸乙酯提取物及其分离的化合物用于预防和治疗脑疾病如阿尔茨海默病中风和帕金森病，由缺血引起的细胞和组织损伤 ，或心血管系统疾病如心肌梗死。

公开(公告)号：WO2003015827A1

公开(公告)日：2003-02-27

申请号：PCT/KR2002/001554

申请日：2002-08-14

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  JAKWANG CO., LTD. ,  KWON, Ick,Chan ,  KIM, In-San ,  JEONG, Seo,Young ,  CHUNG, Hesson ,  CHO, Yong,Woo ,  SON, Yoen,Ju ,  PARK, Chong,Rae ,  SEO, Sang, Bong

Inventor： KWON, Ick,Chan ,  KIM, In-San ,  JEONG, Seo,Young ,  CHUNG, Hesson ,  CHO, Yong,Woo ,  SON, Yoen,Ju ,  PARK, Chong,Rae ,  SEO, Sang, Bong

IPC: A61K47/48

CPC classification number: A61K31/704 ,  A61K47/61 ,  A61K47/6907

Abstract: The present invention relates to an anticancer drug-chitosan complex forming self-aggregates and the preparation method thereof. More precisely, the present invention relates to the anticancer drug-chitosan complex forming self-aggregates in aqueous media composed of a hydrophobic anticancer agent and a hydrophilic chitosan, and the preparation method thereof. The anticancer drug-chitosan complex of the present invention not only works selectively against target tumor tissue but also continues to release the medicine over a long period of time. Besides, the anticancer drug-chitosan complex could have greater amount of drug by adding the anticancer drug into self-aggregates, which is generally limited by chemical bond. Therefore, the anticancer drug-chitosan complex of the present invention can be effectively used for the cancer chemotherapy.

Abstract translation: 本发明涉及形成自聚集体的抗癌药物 - 壳聚糖复合物及其制备方法。 更准确地说，本发明涉及在由疏水性抗癌剂和亲水性壳聚糖组成的水性介质中形成自聚集体的抗癌药物 - 壳聚糖复合物及其制备方法。 本发明的抗癌药物 - 壳聚糖复合物不仅对目标肿瘤组织有选择性的作用，而且还能够长时间地释放药物。 此外，抗癌药物 - 壳聚糖复合物可以通过将抗癌药物加入自聚集体中而具有更大量的药物，其通常受化学键的限制。 因此，本发明的抗癌药物 - 壳聚糖复合物可以有效地用于癌症化疗。

公开(公告)号：WO2003011904A1

公开(公告)日：2003-02-13

申请号：PCT/KR2001/001771

申请日：2001-10-19

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  YU, Yeon-Gyu ,  JIN, Young-Nam ,  YU, Jae-Hoon

Inventor： YU, Yeon-Gyu ,  JIN, Young-Nam ,  YU, Jae-Hoon

IPC: C07K14/47

CPC classification number: C12N9/0036 ,  C07K14/47 ,  C07K2319/00

Abstract: The present invention relates to a C-terminal region protein of human nucleolar phosphoprotein hNopp140 and the gene thereof. Particularly, the present invention relates to a C-terminal region protein of the human nucleolar phosphoprotein hNopp140, which binds specifically to doxorubicin, and the gene encoding the same. C-terminal region protein of the human nucleolar phosphoprotein hNopp140 of the present invention can be effectively used to reduce side effects of the anticancer agent and improve its activity.

Abstract translation: 本发明涉及人核磷酸蛋白hNopp140的C-末端区蛋白及其基因。 特别地，本发明涉及特异性结合多柔比星的人核仁磷酸蛋白hNopp140的C-末端区蛋白及其编码基因。 可以有效地利用本发明的人核仁磷酸蛋白hNopp140的C-末端区蛋白来降低抗癌剂的副作用，提高其活性。

公开(公告)号：WO2002061862A1

公开(公告)日：2002-08-08

申请号：PCT/KR2001/000131

申请日：2001-01-31

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  CHO, Byung-Won ,  CHO, Won-Il ,  KIM, Hyung-Sun ,  YOON, Young-Soo ,  KIM, Un-Sek ,  NAM, Sang-Cheol ,  LEE, Sung-Won ,  PARK, Ho-Young

Inventor： CHO, Byung-Won ,  CHO, Won-Il ,  KIM, Hyung-Sun ,  YOON, Young-Soo ,  KIM, Un-Sek ,  NAM, Sang-Cheol ,  LEE, Sung-Won ,  PARK, Ho-Young

IPC: H01M4/38

CPC classification number: H01M4/04 ,  H01M4/0404 ,  H01M4/0421 ,  H01M4/0426 ,  H01M4/043 ,  H01M4/0435 ,  H01M4/13 ,  H01M4/38

Abstract: The present invention relates to a lithium-metal composite electrode, its preparation method and lithium secondary battery. The lithium-metal composite electrode comprises lithium particles or lithium alloy particles mixed with metal, and it is obtained by simultaneously depositing lithium or a lithium alloy with metal on a current collector using a thin fabrication technique, and pressing the obtained.

Abstract translation: 本发明涉及锂金属复合电极及其制备方法和锂二次电池。 锂金属复合电极包括与金属混合的锂颗粒或锂合金颗粒，并且通过使用薄的制造技术在集电体上同时将锂或锂合金与金属沉积而获得，并且压制所得到的。